anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a Qilong soft capsule and a preparation method. Doctors of traditional Chinese medicine believe that the symptoms of stroke, such as hemiplegia, are often caused due to insufficiency of middle-warmer energy and invasion by pathogens, liver blood stasis and meridian and collateral obstruction as well as qi deficiency and blood stasis. Hemiplegia induced by stroke is suitable to be treated by tonifying qi and activating blood. The Qilong capsule has good protective effects on cerebral injury, has the effect of improving cerebral microcirculation and has antithrombotic and thrombolytic effects. The Qilong soft capsule comprises a capsule shell, wherein the capsule shell contains content. The Qilong soft capsule is characterized in that the content comprises 350-420 parts of radix astragali, 360-450 parts of earthworm, 15-30 parts of Danshen root, 15-28 parts of Chinese angelica, 15-30 parts of red paeony root, 15-30 parts of Szechuan lovage rhizome, 8-15 parts of safflower and 1-5 parts of peach seed by weight; the capsule shell comprises 170-210 parts of gelatin and 200-230 parts of purified water by weight.
Initial treatment: nab-paclitaxel + gemcitabine. Maintenance treatment (after 8 cycles): gemcitabine.
PURPOSE: A cosmetic composition is provided to improve gloss, lubrication, and moisture of hair and to have a hair-setting function, thereby providing nutrients and a hair-styling function by only one product. CONSTITUTION: A cosmetic composition comprises cyclomethicone, cetyl PEG/PPG-10/1 dimethicone, lecithin, isopropyl myristate, dimethicone, cyclomethicone/dimethicone, purified water, glycerin, a acrylate/palmes-25 acrylate copolymer, an alkali agent, and a PVP/VA copolymer. A manufacturing method of the cosmetic composition comprises a step of preparing a mixture A, a mixture B, and a mixture C; a step of putting the mixture A into a mixer; and a step of stirring the mixer while injecting the mixture B into the mixer. The mixture A comprises the cyclomethicone, cetyl PEG/PPG-10/1 dimethicone, lecithin, isopropyl myristate, dimethicone, and cyclomethicone/dimethicone. The mixture B comprises the dimethicone. purified water, glycerin, and acrylate/palmes-25 acrylate copolymer. The mixture C comprises the purified water, alkali agent, and PVP/VA copolymer.
FIELD: medicine. SUBSTANCE: method involves introducing thin catheter through draining tube to approach the found choledocholith and starting supplying calculus-dissolving medicamentous mixture. The external end of the choledochus drain tube is lifted to 16 cm above the axillary median line to create hydrostatic pressure of 160 mm of water column therein. It is kept in this position until complete evacuation of dissolved calculus remnants into the duodenum takes place. The medicamentous mixture is composed of diethyl ether in sterile olive oil in 1:1 proportion. EFFECT: enhanced effectiveness of treatment when treating calculi which diameter is equal to or more than 1 cm; avoided adverse side effects like pains and dyspeptic disorders. 2 cl, 1 dwg
This clinical trial aims to address the scarcity of retinal image datasets in Pakistan by providing a comprehensive digital fundus photograph dataset, accompanied by expert grading. The dataset will encompass retinal images from Pakistani individuals, meticulously labeled by three Vitreo Retinal Specialists. These specialists will assess the presence and severity of common retinal disorders, including No Diabetic Retinopathy (No DR), Mild, Moderate, Severe, Proliferative Diabetic Retinopathy, Clinically Significant Macular Edema (CSME), and Advance diabetic Eye Diseases (ADED). Each image will also be evaluated for diagnostic clarity and the presence of any additional findings. Final grading decisions will be reached through unanimous consensus among the graders, ensuring the dataset's reliability and accuracy. This initiative holds promise for advancing ophthalmic research and improving patient care in Pakistan and beyond.
The postmarketing observational study is observational in nature. Its follow-up is not interventional and is left to the judgment of each physician during the observational period, which defines the survey for each patient. Follow-up of patients should enable two patient visits during this period.

The screening/inclusion visit (Visit 1) will be performed when the decision for Klacid SR therapy in a daily dose of 1000 mg is made. The second visit of the patient will occur 10 - 16 days from the screening/inclusion Visit (upon physician's decision). The physician can change the numbers and time of the visits. As a result, failure to meet these suggested dates will not constitute a breach of the protocol.
INTRODUCTION: No specific study has investigated the characteristics and outcomes of anterior shoulder dislocations in morbidly obese individuals. The purpose of this study was to describe shoulder dislocations in patients with body mass index (BMI) greater than 40.
METHODS: A retrospective review was conducted to identify patients aged 18 years and older with a BMI ≥40 who presented with a shoulder dislocation in a single institution from 2000 to 2020. Dislocation patterns, associated injuries, treatment modalities, and associated complications were recorded.
RESULTS: A significant increase was noted in the number of patients with BMI greater than 40 presenting per year (r2 = -0.831, P < 0.01) over the past 20 years. A significant increase was noted in the average BMI per year in this population (r2 = 0.504, P = 0.028). Fifteen patients (19.5%) experienced at least one recurrent dislocation episode. Ten patients had a Bankart lesion that was associated with an elevated BMI (P = 0.04). Nine patients (11.7%) sustained an associated neurologic injury (no association with BMI).
CONCLUSIONS: Over time, there has been an increase in shoulder dislocations in morbidly obese individuals in the United States, alongside an overall increase in the average BMI of patients who present with shoulder dislocations.
Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
BACKGROUND: Machine Learning models have been applied in various healthcare fields, including Audiology, to predict disease outcomes. The prognosis of sudden sensorineural hearing loss is difficult to predict due to the variable course of the disease. Hence, researchers have attempted to utilize ML models to predict the outcome of patients with sudden sensorineural hearing loss. The objectives of this study were to review the performance of these machine learning models and assess their applicability in real-world settings.
METHODS: A systematic search was conducted in PubMed, Web of Science and Scopus. Only studies that built machine learning prediction models were included, and studies that used algorithms such as logistic regression only for the purpose of adjusting for confounding variables were excluded. The risk of bias was assessed using the Prediction model Risk of Bias Assessment Tool (PROBAST).
RESULTS: After screening, a total of 7 papers were eligible for synthesis. In total, these studies built 48 ML models. The most common utilized algorithms were Logistic Regression, Support Vector Machine (SVM) and boosting. The area under the curve of the receiver operating characteristic curve ranged between 0.59 and 0.915. All of the included studies had a high risk of bias; hence there are concerns regarding their applicability.
CONCLUSION: Although these models showed great performance and promising results, future studies are still needed before these models can be applied in a real-world setting. Future studies should employ multiple cohorts, different feature selection methods, and external validation to further validate the models' applicability.
FIELD: medicine, stomatology. SUBSTANCE: the suggested system includes detachable bottom plate of sufficient flexibility for easy taking the shape of mouth cavity surface, when one should apply delivery system on it together with compositions for taking care of mouth cavity applied so that during this process composition has contacts with mouth cavity. Moreover, the suggested composition includes organosiloxane resin, viscosity modifier and substance for taking care of mouth cavity. There are, also, described delivery systems in which composition for taking care of mouth cavity additionally includes liquid polymers based upon diorganopolysiloxane and, also, they may include carriers for dissolving organosiloxane resin and liquid polymers. It is, also, mentioned the method for applying these delivery systems. This system provides prolonged release of active ingredients without periodic repeated application in short periods of time. EFFECT: higher efficiency of delivering. 28 cl, 11 dwg, 7 tbl
<P>PROBLEM TO BE SOLVED: To provide a new protein useful for screening agonists/antagonists, and the like.  <P>SOLUTION: This human being-originated protein or its salt. The DNA encoding the protein. A method for determining a ligand for the protein. A method for screening a compound for screening the bondability of the ligand to the protein. A kit for screening the compound for screening the bondability of the ligand to the protein. The compound obtained by the screening or its salt, and the like. The human being-originated protein or the DNA encoding the protein can be used for (1) the determination of the ligand for the protein, (2) a medicine for preventing and/or treating a disease related to the function failure of the protein, (3) the screening of a compound for changing the bondability of the ligand to the protein, and the like.  <P>COPYRIGHT: (C)2003,JPO
Resveratrol (RES) has been reported to prevent hyperuricemia (HUA); however, its effect on intestinal uric acid metabolism remains unclear. This study evaluated the impact of RES on intestinal uric acid metabolism in mice with HUA induced by a high-fat diet (HFD). Moreover, we revealed the underlying mechanism through metagenomics, fecal microbiota transplantation (FMT), and 16S ribosomal RNA analysis. We demonstrated that RES reduced the serum uric acid, creatinine, urea nitrogen, and urinary protein levels, and improved the glomerular atrophy, unclear renal tubule structure, fibrosis, and renal inflammation. The results also showed that RES increased intestinal uric acid degradation. RES significantly changed the intestinal flora composition of HFD-fed mice by enriching the beneficial bacteria that degrade uric acid, reducing harmful bacteria that promote inflammation, and improving microbial function via the upregulation of purine metabolism. The FMT results further showed that the intestinal microbiota is essential for the effect of RES on HUA, and that Lactobacillus may play a key role in this process. The present study demonstrated that RES alleviates HFD-induced HUA and renal injury by regulating the gut microbiota composition and the metabolism of uric acid.
Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans.  The invention is based upon the identification of genes that are amplified in the genome of tumor cells.  Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis.  Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as predictors of the prognosis of tumor treatment. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.  Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
For schizophrenia patients taking oral antipsychotic medications, a long-acting injectable formulation of a antipsychotic medication may eliminate the need for daily medication and enhance patient compliance with the treatment regimen. This is an open-label, non-randomized study of a formulation of risperidone (coated microspheres) injected into the muscle at 2 week intervals over 12 weeks in patients with schizophrenia. The study has two phases: during the first 4 weeks, patients continue treatment with their present medication (haloperidol, quetiapine fumarate, or olanzapine); during the second phase of 12 weeks, patients receive the injectable formulation of risperidone, while continuing to receive their present medication for 3 weeks until the risperidone long-acting injectable reaches effective drug levels. For the remainder of the 12-week treatment phase, patients receive only injectable risperidone every 2 weeks. Safety evaluations include the incidence, type, and severity of treatment-emergent adverse events throughout the study; vital signs (pulse, blood pressure), clinical laboratory tests (hematology, biochemistry, urinalysis), electrocardiograms (ECGs), and extrapyramidial symptoms are also monitored at specified intervals. Assessments of effectiveness include the Positive and Negative Syndrome Scale (PANSS) and overall severity of illness measured by the Clinical Global Impression (CGI) scale. The study hypothesis is that long-acting injectible risperidone will be well-tolerated in the treatment of patients with schizophrenia after switching from treatment with an oral antipsychotic. Risperidone injections (25 milligrams\[mg\]) every 2 weeks for 12 weeks. Investigator may adjust dosage to 37.5mg or 50 mg (maximum) or supplement risperidone injections with risperidone tablets (1mg), according to symptoms and treatment response.
The arteriovenous fistula (AVF) is commonly faced with stenosis at the juxta-anastomotic (JXA) region of the vein. Implantation of a flexible nitinol stent across the stenosed JXA has led to the retention of functioning AVFs leading to the resulting AVF geometry being distinctly altered, thereby affecting the haemodynamic environment within it. In this study, large eddy simulations of the flow field within a patient-specific AVF geometry before and after stent implantation were conducted to detail the change in flow features. Although the diseased AVF had much lower flow rates, adverse flow features, such as recirculation zones and swirling flow at the anastomosis, and jet flow at the stenosis site were present. Larger velocity fluctuations (leading to higher turbulent kinetic energy) stemming from these flow features were apparent in the diseased AVF compared to the stented AVF. The unsteadiness at the stenosis created large regions of wall shear stress (WSS) fluctuations downstream of the stenosis site that were not as apparent in the stented AVF geometry. The larger pressure drop across the diseased vein, compared to the stented vein, was primarily caused by the constriction at the stenosis, potentially causing the lower flow rate. Furthermore, the WSS fluctuations in the diseased AVF could lead to further disease progression downstream of the stenosis. The change in bulk flow unsteadiness, pressure drop, and WSS behaviour confirms that the haemodynamic environment of the diseased AVF has substantially improved following the flexible stent implantation.
Various surgical hubs are disclosed. The surgical hub is configured to communicate with a surgical instrument. The surgical hub includes a processor and a memory coupled to the processor. The memory stores instructions executable by the processor to: a first data set associated with a surgical procedure is received. A first data set is generated at a first time. A second data set associated with efficacy of the surgical procedure is also received. A second data set is generated at a second time. The second time is separate and distinct from the first time. The processor also executes instructions that: anonymizing the first data set and the second data set by removing information identifying the patient, the procedure, or a predetermined time of the procedure; and storing the first anonymized data set and the second anonymized data set to generate surgically-grouped data pairs.
### Risk Summary 

There are no available data on Kerendia use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies have shown developmental toxicity at exposures about 4 times those expected in humans. (see Data). The clinical significance of these findings is unclear. 

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

### Data 

####  Animal Data

In the embryo-fetal toxicity study in rats, finerenone resulted in reduced placental weights and signs of fetal toxicity, including reduced fetal weights and retarded ossification at the maternal toxic dose of 10 mg/kg/day corresponding to an AUCunbound of 19 times that in humans. At 30 mg/kg/day, the incidence of visceral and skeletal variations was increased (slight edema, shortened umbilical cord, slightly enlarged fontanelle) and one fetus showed complex malformations including a rare malformation (double aortic arch) at an AUCunbound of about 25 times that in humans. The doses free of any findings (low dose in rats, high dose in rabbits) provide safety margins of 10 to 13 times for the AUCunbound expected in humans. 

When rats were exposed during pregnancy and lactation in the pre- and postnatal developmental toxicity study, increased pup mortality and other adverse effects (lower pup weight, delayed pinna unfolding) were observed at about 4 times the AUCunbound expected in humans. In addition, the offspring showed slightly increased locomotor activity, but no other neurobehavioral changes starting at about 4 times the AUCunbound expected in humans. The dose free of findings provides a safety margin of about 2 times for the AUCunbound expected in humans.
Dicyclomine hydrochloride tablets needs to be used with caution in conditions characterized by tachyarrhythmia such as thyrotoxicosis, congestive heart failure and in cardiac surgery, where they may further accelerate the heart rate. Investigate any tachycardia before administration of dicyclomine hydrochloride tablets. Care is required in patients with coronary heart disease, as ischemia and infarction may be worsened, and in patients with hypertension [see Error! Hyperlink reference not valid. (Error! Hyperlink reference not valid.)].
GLP-1 agonist peptide conjugates, methods of forming the conjugates, and methods of using the conjugates are described. Peptide conjugates include a GLP-1 agonist peptide (e.g., GLP-1 or a functional equivalent thereof), a linking agent, and a targeting moiety. Linking agents can include polymeric linkers such as PEG linkers, e.g., monodisperse PEG linkers. Targeting moieties can target tissue or cell types. Targeting moieties can include sulfhydryl groups for targeting hydroxyapatite of bone tissue. Conjugates can exhibit extended plasma half-life and can target bone tissue for use as a reservoir for extended delivery of the peptide.
PURPOSE:To obtain the title fine liposome having about 0.01-0.03mu size by simultaneously dispersing a phospholipid and 1-15wt%, based on the phosphlipid, hydrophilic nonionicsurfactant in water to produce the liposome. CONSTITUTION:Phospholipids such as animal and vegetable lecithinins, e.g., egg yolk lecithin and soybean lecithin, and 4n15wt%, based on the phospholipids, hydrophilic nonionic surfactant are simultaneously dispersed in water to produce the liposome. The hydrophilic nonionic surfactant must be transprently dissolved in water, and the surfactant of >=12 HLB is used. Polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene hydrogenated castor oil, etc., can be exemplified as the emobodiment. When the phospholipid and the surfactant are dispersed in water, polyhydric alcohols, inorg. and org. salts, etc., can be used as the dispersion assistant.
Administering aerosol drugs through the nasal pathway is a common early treatment for children with adenoid hypertrophy (AH). To enhance therapeutic efficacy, a deeper understanding of nasal drug delivery in the nasopharynx is essential. This study uses an integrated experimental, numerical modelling approach to investigate the delivery process of both the aerosol mask delivery system (MDS) and the bi-directional delivery system (BDS) in the pediatric nasal airway with AH. The combined effect of respiratory flow rates and particle size on delivery efficiency was systematically analyzed. The results showed that the nasopharyngeal peak deposition efficiency (DE) for BDS was approximately 2.25-3.73 times higher than that for MDS under low-flow, resting and high-flow respiratory conditions. Overall nasopharyngeal DEs for MDS were at a low level of below 16 %. For each respiratory flow rate, the BDS tended to achieve higher peak DEs (36.36 % vs 9.74 %, 37.80 % vs 14.01 %, 34.58 % vs 15.35 %) at smaller particle sizes (15 µm vs 17 µm, 10 µm vs 14 µm, 6 µm vs 9 µm). An optimal particle size exists for each respiratory flow rate, maximizing the drug delivery efficiency to the nasopharynx. The BDS is more effective in delivering drug aerosols to the nasal cavity and nasopharynx, which is crucial for early intervention in children with AH.
Although aging occurs in all periods in the human body, physical, mental and physical aging becomes visible as you get older. This situation is caused by physiological aging, environmental factors, existing chronic diseases and related symptoms. Today, increasing life expectancy and aging population must be taken into account. Since the age-related symptoms of elderly individuals are compatible with the consequences of aging, they can be ignored as a natural process, and therefore its progression cannot be prevented. With our project, it is aimed that screening for sarcopenia will be an exemplary study throughout Turkey and this type of screening will be widespread. In addition, it is aimed to divide elderly individuals into groups as presarcopenia, sarcopenia and severe sarcopenia, and to provide necessary guidance, protective and prevention approaches, strengthening and exercise training.

Demographic data of elderly individuals (age, gender, height, weight, BMI (Body mass index will be obtained by dividing body weight (kg), height (m) squared) occupation, etc.), chronic diseases (hypertension, diabetes, chronic obstructive pulmonary disease) (COPD), rheumatic diseases), drugs used, smoking, alcohol habits, and assistive device use, and the 'Clinical Vulnerability Scale' to evaluate the cognitive status of individuals through the 'Mini Nutritional Assessment form (MNA)'. 'Standardized Mini-Mental Test' to assess balance and walking, 'Tinetti balance and walking test' to evaluate balance and walking, 'Falling Risk Self-Assessment Scale' to assess falls, 'Functional Independence and Challenge Scale' to measure functional independence in activities of daily living. 'Short Physical Performance Test' (KFPT), Sarcopenia screening test (SA) to assess physical fitness RC-F), it is planned to use the Physical Activity Scale for the Elderly (PASE) to evaluate the level of physical activity, to use hand dynamometer, to evaluate muscle strength, and to measure the muscle mass of individuals with an inbody bioimpedance device.